All In Biotech

Drug Trial Radar · NCT00359762

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)

Last checked: Nov 20, 2026Latest source record: Sep 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,029 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,029

Actual

Start

Sep 2006

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Aug 2, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea (glimepiride) on long-term glycemic control and beta-cell function.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • exenatideDrug

    subcutaneous injection (5mcg or 10mcg), twice a day

  • glimepirideDrug

    oral tablet (titrated to maximally tolerated dose), once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Treatment FailureTime frame: Baseline to end of Period II (up to 4.5 years)
  2. Time to Treatment FailureTime frame: Baseline to end of Period II (up to 4.5 years)

Locations

114 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Graz, Austria

  • Research Site

    Innsbruck, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Beroun, Czechia

  • Research Site

    České Budějovice, Czechia

  • Research Site

    Hradec Králové, Czechia

  • Research Site

    Liberec, Czechia

  • Research Site

    Písek, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Třebíč, Czechia

  • Research Site

    Helsinki, Finland

  • Research Site

    Kuopio, Finland

  • Research Site

    Pori, Finland

  • Research Site

    Vaasa, Finland

  • Research Site

    Alençon, France

  • Research Site

    Bois-Guillaume, France

  • Research Site

    Bourg-des-Comptes, France

  • Research Site

    Broglie, France

  • Research Site

    Bron, France

  • Research Site

    Fléville-devant-Nancy, France

  • Research Site

    Le Creusot, France

  • Research Site

    Le Mans, France

  • Research Site

    Loudun, France

  • Research Site

    Montigny-lès-Metz, France

  • Research Site

    Nevers, France

  • Research Site

    Strasbourg, France

  • Research Site

    Thouars, France

  • Research Site

    Tours, France

  • Research Site

    Valréas, France

  • Research Site

    Vénissieux, France

  • Research Site

    Vihiers, France

  • Research Site

    Altona, Germany

  • Research Site

    Aschaffenburg, Germany

  • Research Site

    Bad Staffelstein, Germany

  • Research Site

    Dresden, Germany

  • Research Site

    Eisenach, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Essen Schonnebeck, Germany

  • Research Site

    Falkensee, Germany

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.